---
figid: PMC6855178__nihms-1058736-f0001
figlink: /pmc/articles/PMC6855178/figure/F1/
number: F1
caption: 'Ligand binding of RTKs leads to many downstream effects. Proangiogenic RTKs
  (VEGFR, PDGFR, and FGFR) are labeled in blue, whereas growth factor ligand binding
  to RTKs is colored orange. Simplified mechanisms of the MAPK pathway (left) and
  mTOR pathway (right) are labeled in the tumor cell. Activation of HIF-α occurs in
  states of hypoxia and through lack of inhibition from a nonfunctional VHL gene.
  It leads to synthesis of VEGF, PDGF, and FGF. This can lead to MAPK activation in
  endothelial cells, depicted on the left side of the diagram. Through FKBP is the
  site of action of mTOR inhibitors everolimus and temsirolimus and is labeled in
  orange. Bevacizumab is a monoclonal antibody directed against VEGF. TKIs include
  sorafenib, sunitinib, axitinib, pazopanib, cabozantinib, and Ienvatinib. The aforementioned
  TKIs inhibit multiple RTKs. RTKs of importance are inhibited by the following TKIs:
  axitinib (VEGFR, PDGFR, c-KIT), sunitinib (VEGFR, PDGFR, RET, c-KIT), sorafenib
  (VEGFR, PDGFR, RET, c-KIT, Raf kinases), pazopanib (VEGFR, PDGFR, FGFR, c-KIT, RET),
  Ienvatinib (VEGFR, PDGFR, FGFR, c-KIT, RET), and cabozantinib (VEGFR, c-MET, AXL,
  c-KIT, RET).Abbreviations: ERK, extracellular signal-regulated kinase; FGF, fibroblast
  growth factor; FGFR, fibroblast growth factor receptor; FKBP, FK506-binding protein;
  GAS6, growth arrest-specific 6; HGF, hepatocyte growth factor; MAPK, mitogen-activated
  protein kinase; MEK, mitogen-activated protein kinase kinase; PDGF, platelet-derived
  growth factor; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3
  kinase; RTK, receptor tyrosine kinase; SCF, stem cell factor; TKI, tyrosine kinase
  inhibitor; VEGFR, VEGF receptor; VHL, von Hippel–Lindau.'
pmcid: PMC6855178
papertitle: Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
reftext: David M. Gill, et al. Am Soc Clin Oncol Educ Book. ;37:319-329.
pmc_ranked_result_index: '167423'
pathway_score: 0.9725982
filename: nihms-1058736-f0001.jpg
figtitle: Action of Targeted Therapies in Metastatic Renal Cell Carcinoma
year: ''
organisms:
- Homo sapiens
ndex: fe8ffb77-debf-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6855178__nihms-1058736-f0001.html
  '@type': Dataset
  description: 'Ligand binding of RTKs leads to many downstream effects. Proangiogenic
    RTKs (VEGFR, PDGFR, and FGFR) are labeled in blue, whereas growth factor ligand
    binding to RTKs is colored orange. Simplified mechanisms of the MAPK pathway (left)
    and mTOR pathway (right) are labeled in the tumor cell. Activation of HIF-α occurs
    in states of hypoxia and through lack of inhibition from a nonfunctional VHL gene.
    It leads to synthesis of VEGF, PDGF, and FGF. This can lead to MAPK activation
    in endothelial cells, depicted on the left side of the diagram. Through FKBP is
    the site of action of mTOR inhibitors everolimus and temsirolimus and is labeled
    in orange. Bevacizumab is a monoclonal antibody directed against VEGF. TKIs include
    sorafenib, sunitinib, axitinib, pazopanib, cabozantinib, and Ienvatinib. The aforementioned
    TKIs inhibit multiple RTKs. RTKs of importance are inhibited by the following
    TKIs: axitinib (VEGFR, PDGFR, c-KIT), sunitinib (VEGFR, PDGFR, RET, c-KIT), sorafenib
    (VEGFR, PDGFR, RET, c-KIT, Raf kinases), pazopanib (VEGFR, PDGFR, FGFR, c-KIT,
    RET), Ienvatinib (VEGFR, PDGFR, FGFR, c-KIT, RET), and cabozantinib (VEGFR, c-MET,
    AXL, c-KIT, RET).Abbreviations: ERK, extracellular signal-regulated kinase; FGF,
    fibroblast growth factor; FGFR, fibroblast growth factor receptor; FKBP, FK506-binding
    protein; GAS6, growth arrest-specific 6; HGF, hepatocyte growth factor; MAPK,
    mitogen-activated protein kinase; MEK, mitogen-activated protein kinase kinase;
    PDGF, platelet-derived growth factor; PDGFR, platelet-derived growth factor receptor;
    PI3K, phosphatidylinositol-3 kinase; RTK, receptor tyrosine kinase; SCF, stem
    cell factor; TKI, tyrosine kinase inhibitor; VEGFR, VEGF receptor; VHL, von Hippel–Lindau.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT3
  - AKT1
  - AKT2
  - AXL
  - KIT
  - MET
  - MAPK1
  - MAPK3
  - FGF12
  - FGF1
  - FGF2
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FGF10
  - FGF11
  - FGF13
  - FGF14
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF18
  - FGF17
  - FGF16
  - FGF19
  - FGFR2
  - FGFR1
  - FGFRL1
  - FGFR4
  - FGFR3
  - GAS6
  - HGF
  - EPAS1
  - HIF1A
  - HIF3A
  - MAP2K1
  - MAP2K2
  - MTOR
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PDGFRB
  - PDGFRA
  - ARAF
  - RAF1
  - BRAF
  - HRAS
  - KRAS
  - NRAS
  - RET
  - KITLG
  - VEGFD
  - PGF
  - VEGFA
  - VEGFB
  - VEGFC
  - FLT1
  - FLT4
  - KDR
  - VHL
  - Temsirolimus
  - Pazopanib
  - Lenvatinib
  - Cabozantinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
genes:
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: AXL
  symbol: AXL
  source: hgnc_symbol
  hgnc_symbol: AXL
  entrez: '558'
- word: c-KIT
  symbol: C-Kit
  source: hgnc_alias_symbol
  hgnc_symbol: KIT
  entrez: '3815'
- word: c-MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF12
  entrez: '2257'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF1
  entrez: '2246'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF2
  entrez: '2247'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF3
  entrez: '2248'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF4
  entrez: '2249'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF5
  entrez: '2250'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF6
  entrez: '2251'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF7
  entrez: '2252'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF8
  entrez: '2253'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF9
  entrez: '2254'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF10
  entrez: '2255'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF11
  entrez: '2256'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF13
  entrez: '2258'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF14
  entrez: '2259'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF20
  entrez: '26281'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF21
  entrez: '26291'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF22
  entrez: '27006'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF23
  entrez: '8074'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF18
  entrez: '8817'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF17
  entrez: '8822'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF16
  entrez: '8823'
- word: FGF
  symbol: FGF
  source: bioentities_symbol
  hgnc_symbol: FGF19
  entrez: '9965'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR2
  entrez: '2263'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR1
  entrez: '2260'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFRL1
  entrez: '53834'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR4
  entrez: '2264'
- word: FGFR
  symbol: FGFR
  source: bioentities_symbol
  hgnc_symbol: FGFR3
  entrez: '2261'
- word: GAS6
  symbol: GAS6
  source: hgnc_symbol
  hgnc_symbol: GAS6
  entrez: '2621'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: HIFA
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIFA
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIFA
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: RET
  symbol: RET
  source: hgnc_symbol
  hgnc_symbol: RET
  entrez: '5979'
- word: SCF
  symbol: SCF
  source: hgnc_alias_symbol
  hgnc_symbol: KITLG
  entrez: '4254'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Pazopanib
  source: MESH
  identifier: C516667
- word: Lenvatinib
  source: MESH
  identifier: C531958
- word: Cabozantinib
  source: MESH
  identifier: C558660
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC6855178__F1
redirect_from: /figures/PMC6855178__F1
figtype: Figure
---
